Pharmacokinetics of cefuroxime in infants and neonates undergoing cardiac surgery

Abstract

The routine dosing regimen provided was sufficient for prophylaxis, but continuous dosing can provide a higher percentage of ƒT > MIC.

Population pharmacokinetics of cefuroxime and uptake into hip and spine bone of patients undergoing orthopaedic surgery

“…used a somewhat different design: less samples (5 vs 8) were taken from patients after cefuroxime application, they also studied patients with impaired renal function (receiving half the usual dose of cefuroxime) and gave cefuroxime three times daily 1.5 g cefuroxime (they treated patients in the infectious disease unit with symptoms and signs of bacterial infection thought to be treatable with cefuroxime) whereas we gave a single dose of 1.5 g cefuroxime (using prophylactic treatment). Estimates of pharmacokinetic parameters were in accordance with those in earlier studies …”

“…Estimates of pharmacokinetic parameters were in accordance with those in earlier studies. [18][19][20] Others have had measured concentrations of cefuroxime in plasma and bone of the same patient and at similar Samples were taken 55 AE 24 min (mean (SD)) after drug infusion. It must be noted that the time that serum levels exceed the MIC (T > MIC) could be a more relevant parameter characterizing cephalosporins than the MIC itself.…”

The Year in Review: Anesthesia for Congenital Heart Disease 2018

“…The authors propose a continuous dosing simulation from their study supporting a cefuroxime regimen of 25 mg/kg as a primary bolus for the patient and the CPB prime, followed by 5 mg/kg/h continuous infusion throughout the perioperative course to maintain a cefuroxime concentration above 32 mg/L in pediatric cardiac surgical patients. 28 What is helpful with this cefuroxime study by Gertler and colleagues, 28 is that it supports findings from an earlier pharmacokinetic study in older children undergoing cardiovascular surgery in which a similar dosing strategy was found to be appropriate. 29 The review by Jaworski and colleagues 24 is helpful because it highlights the need for prospective randomized trials in children to help establish the correct dose and dosing schedule of antibiotics to assess the efficacy and safety of SAP in pediatric cardiac surgery.…”

Population pharmacokinetic evaluation of cefuroxime in perioperative antibiotic prophylaxis during and after cardiopulmonary bypass

“…Our pharmacokinetic/pharmacodynamic study of cefuroxime as PAP in cardiac surgery differs from several previous investigations, 27,29–32 some of which were merely descriptively without the development of a pharmacokinetic model 33–35 …”

“…In this study of cefuroxime in cardiac surgery, we used plasma concentrations taken Our PK/PD-study of cefuroxime as PAP in cardiac surgery differs from several previous investigations [27,[29][30][31][32], some of which were merely descriptively without the development of a pharmacokinetic model [33][34][35].…”